Briefs

Global license provides access to InforSense integrative analytics technology across all AstraZeneca Research and Development (R&D) sites

AstraZeneca scientists to use InforSense KDE to enhance drug discovery decision-making

London, UK and Cambridge, MA, USA, December 15, 2005 - InforSense Ltd, the leader in integrative analytics platforms, today announced that AstraZeneca (NYSE, LSE, SSE: AZN) has strengthened their strategic commitment to InforSense technology across their research and development organization through a new multi-year global licensing deal. Scientists at AstraZeneca R&D sites will use InforSense�s workflow-based integrative analytics environment, InforSense� KDE, to derive research intelligence and enhance productivity in their core drug discovery programs. Financial terms of the agreement were not disclosed.

For further information on InforSense products and solutions, visit www.inforsense.com.